Mezigdomide
An investigational treatment for Multiple Myeloma.
The same compound appears under different names depending on the context. Here is how to identify Mezigdomide wherever you encounter it, plus the key facts at a glance.
- Generic name
- Mezigdomide
- Development code
- CC-92480
- Drug class
- CELMoD agent
- Manufacturer
- Bristol Myers Squibb
- How it's taken
- Taken by mouth at a 1.
An oral myeloma drug from Bristol Myers Squibb, a next step beyond lenalidomide and pomalidomide, under FDA review in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma with a decision due May 13, 2027. In the Phase 3 SUCCESSOR-2 trial it more than doubled the time before the disease progressed.
Where Mezigdomide fits
Mezigdomide is aimed at the large group of patients whose myeloma has already been exposed to a proteasome inhibitor, an immunomodulatory drug and an anti-CD38 antibody, where the current choices include CAR T cell therapy, bispecific antibodies, selinexor-based regimens and retreatment with older combinations. Unlike CAR T and most bispecifics it is a pill, taken with a standard carfilzomib backbone, which may matter for people who cannot reach a cell therapy center or wait for manufacturing. The trade-off visible in SUCCESSOR-2 is more severe neutropenia and infection than carfilzomib and dexamethasone alone.
How Mezigdomide works
Lenalidomide (Revlimid) and pomalidomide (Pomalyst) work by binding a protein called cereblon and redirecting it to tag 2 other proteins, Ikaros and Aiolos, for destruction. Myeloma cells need those 2 proteins to survive, and removing them also wakes up the immune system against the cancer. Mezigdomide was designed to do the same job more completely: Bristol Myers Squibb describes it as optimized to modulate cereblon for maximal and rapid degradation of Ikaros and Aiolos. The practical hope is that it works in people whose myeloma has stopped responding to lenalidomide, which was true of 75.8% of patients in SUCCESSOR-2.
Mechanism: Oral cereblon E3 ligase modulator (CELMoD) that drives rapid degradation of the Ikaros and Aiolos proteins myeloma cells depend on
Side effects and safety
Mezigdomide is taken with carfilzomib and dexamethasone, so the trial numbers reflect the combination. In SUCCESSOR-2, grade 3 or 4 adverse events occurred in 83.7% of patients on the mezigdomide combination versus 56.5% on carfilzomib and dexamethasone alone. Low neutrophils of grade 3 or 4 occurred in 61.1% versus 9.1%, and infections in 34.0% versus 15.6%. There is no US label yet, so the final warnings and monitoring schedule are not known; the related drugs lenalidomide and pomalidomide carry boxed warnings for birth defects and blood clots and are dispensed only through restricted programs, and it would be reasonable to expect similar precautions.
This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.
Taking Mezigdomide
Taken by mouth at a 1.0 mg dose in SUCCESSOR-2, alongside carfilzomib infusions and dexamethasone. The exact days-on and days-off schedule will be set by the FDA label.
Clinical trial results
SUCCESSOR-2 (NCT05552976) is a Phase 3 trial that compared mezigdomide plus carfilzomib and dexamethasone (MeziKd) with carfilzomib and dexamethasone (Kd) in relapsed or refractory multiple myeloma, after a first stage that settled the 1.0 mg dose. The analysis included 479 patients, 288 on MeziKd and 191 on Kd; the median age was 68, a quarter were 75 or older, the median number of prior therapies was 2, and 92.1% had already been treated with all 3 main drug classes, with 85.8% refractory to an anti-CD38 antibody and 75.8% refractory to lenalidomide. Median progression-free survival was 18.0 months with MeziKd versus 8.3 months with Kd, a 52% reduction in the risk of progression or death (hazard ratio 0.48, p below 0.0001). The overall response rate was 80.2% versus 53.4%, and 26.7% versus 8.9% reached a complete response or better. Median overall survival had not been reached at a median follow-up of 10.6 months. The results were presented at the American Society of Clinical Oncology meeting in May 2026 and published in The Lancet. A second Phase 3 trial, SUCCESSOR-1, is comparing mezigdomide with a different standard regimen and is ongoing.
Main registered trial: NCT05552976 on ClinicalTrials.gov. Check it for the current status, sites and contacts before asking about enrollment.
Development history
Bristol Myers Squibb developed mezigdomide as the lead of its CELMoD class, a successor to the immunomodulatory drugs it inherited with Celgene. SUCCESSOR-2 results were announced on May 29, 2026 and presented as a late-breaking abstract at ASCO 2026. On July 13, 2026 the FDA accepted the new drug application for mezigdomide with carfilzomib and dexamethasone in relapsed or refractory multiple myeloma and set a target action date of May 13, 2027.
Explore Multiple Myeloma trials
Other Multiple Myeloma treatments
Common questions about Mezigdomide
▸What is Mezigdomide?
An oral myeloma drug from Bristol Myers Squibb, a next step beyond lenalidomide and pomalidomide, under FDA review in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma with a decision due May 13, 2027. In the Phase 3 SUCCESSOR-2 trial it more than doubled the time before the disease progressed.
▸How does Mezigdomide work?
Lenalidomide (Revlimid) and pomalidomide (Pomalyst) work by binding a protein called cereblon and redirecting it to tag 2 other proteins, Ikaros and Aiolos, for destruction. Myeloma cells need those 2 proteins to survive, and removing them also wakes up the immune system against the cancer. Mezigdomide was designed to do the same job more completely: Bristol Myers Squibb describes it as optimized to modulate cereblon for maximal and rapid degradation of Ikaros and Aiolos. The practical hope is that it works in people whose myeloma has stopped responding to lenalidomide, which was true of 75.8% of patients in SUCCESSOR-2.
▸What are the side effects of Mezigdomide?
Mezigdomide is taken with carfilzomib and dexamethasone, so the trial numbers reflect the combination. In SUCCESSOR-2, grade 3 or 4 adverse events occurred in 83.7% of patients on the mezigdomide combination versus 56.5% on carfilzomib and dexamethasone alone. Low neutrophils of grade 3 or 4 occurred in 61.1% versus 9.1%, and infections in 34.0% versus 15.6%. There is no US label yet, so the final warnings and monitoring schedule are not known; the related drugs lenalidomide and pomalidomide carry boxed warnings for birth defects and blood clots and are dispensed only through restricted programs, and it would be reasonable to expect similar precautions.
▸How is Mezigdomide taken?
Taken by mouth at a 1.0 mg dose in SUCCESSOR-2, alongside carfilzomib infusions and dexamethasone. The exact days-on and days-off schedule will be set by the FDA label.
▸Is Mezigdomide FDA approved?
Not yet. Mezigdomide is under FDA review for Multiple Myeloma; Bristol Myers Squibb has filed an application and a decision is due May 13, 2027. The FDA calendar page tracks the outcome.
▸When will the FDA decide on mezigdomide?
The FDA has set a target action date of May 13, 2027 for mezigdomide in combination with carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. The application was accepted on July 13, 2026.
▸Is mezigdomide FDA approved?
No. As of October 2026 mezigdomide is investigational and under FDA review. It has not been approved anywhere.
▸How is mezigdomide different from lenalidomide and pomalidomide?
All 3 work through the same protein, cereblon, to destroy the Ikaros and Aiolos proteins myeloma cells need. Mezigdomide belongs to a newer class called CELMoDs, built to bind cereblon more effectively and degrade those proteins faster and more completely. In SUCCESSOR-2 it worked in a population where 75.8% of patients were already refractory to lenalidomide.
▸What did the SUCCESSOR-2 trial show?
In 479 patients with relapsed or refractory myeloma, mezigdomide plus carfilzomib and dexamethasone kept the disease from progressing for a median of 18.0 months compared with 8.3 months for carfilzomib and dexamethasone alone, a 52% lower risk of progression or death. Response rates were 80.2% versus 53.4%. Grade 3 or 4 neutropenia (61.1% versus 9.1%) and infections (34.0% versus 15.6%) were more common with mezigdomide.
Sources and references
Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.
- Bristol Myers Squibb · 2026-05-29. Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma. https://news.bms.com/news/corporate-financial/2026/Bristol-Myers-Squibb-Announces-CELMoD-Mezigdomide-Reduces-Risk-of-Disease-Progression-or-Death-by-More-than-50-vs--Standard-of-Care-in-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx
- Bristol Myers Squibb · 2026-07-13. U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma. https://news.bms.com/news/details/2026/U-S--Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Mezigdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma/default.aspx
- U.S. National Library of Medicine. A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2), NCT05552976. https://clinicaltrials.gov/study/NCT05552976